Trial site
Specjalistyczna Przychodnia Lekarska Alergo-Med Sp. z o.o
Poznan, Greater Poland Voivodeship 61-578, PolandEU-13 widening countryNot linked to an institution yet
- 15running trials
- 15closed trials
The trials here
What the 30 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 211 trials
- Phase 41 trial
- Status
- Completed14 trials
- Recruiting7 trials
- Active, not recruiting6 trials
- Not yet recruiting2 trials
- Terminated1 trial
- Lead sponsor
- Chiesi Farmaceutici S.p.A.5 trials
- AstraZeneca4 trials
- GlaxoSmithKline2 trials
- Novartis Pharmaceuticals2 trials
- AbbVie1 trial
- and 16 more
Running trials
Recruiting
A Prospective, Randomized, Open-label, Multicentre Study to Compare the Safety of PURETHAL Mites Mixture 50,000 AUeq/mL Rush Up-Dosing Regimen with the Conventional Up-Dosing Regimen in Adult Participants with Allergic House Dust Mite Rhinitis/Rhinoconjunctivitis with or without Asthma.
2026-526908-72-00· Phase 2· HAL Allergy B.V.· Source
Not yet recruiting
Clinical trial to assess the efficacy and safety of a vaccine for grass pollen allergy.
2026-526100-73-00· Phase 3· Inmunotek S.L.· Source
Recruiting
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial
2025-524078-40-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma
2025-522640-41-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· Phase 2· Eli Lilly and Company· Source
Contact: Danuta Madra-Rogacka (principal investigator)
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078· Phase 2· Upstream Bio Inc.· Source
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· Phase 3· GlaxoSmithKline· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· Phase 2· Inmagene LLC· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023· Phase 3· Celldex Therapeutics· Source
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· Phase 3· AstraZeneca· Source
Active, not recruiting
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· Phase 3· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
NCT06920771· Phase 3· HAL Allergy· Source
Completed
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Spontaneous Urticaria (CSU) to assess if it is effective and safe.
2023-504799-94-00· Phase 2· Escient Pharmaceuticals Inc.· Source
Completed
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy
2022-502854-16-00· Phase 2· Rapt Therapeutics Inc.· Source
Completed
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy
2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Terminated
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
NCT05935332· Phase 2· RAPT Therapeutics, Inc., a member of the GSK plc group of companies· Source
Completed
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580· Phase 4· AbbVie· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2)
2023-507665-25-00· Phase 3· Areteia Therapeutics Inc.· Source
Completed
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
NCT05748600· Phase 3· Areteia Therapeutics· Source
Completed
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
NCT05398263· Phase 3· AstraZeneca AB· Source
Completed
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy
NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878· Phase 3· AstraZeneca· Source
Completed
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
NCT04053634· Phase 3· AstraZeneca· Source
Report an error